Generic Vascepa (icosapent ethyl) players in the US will “not have access to sufficient quantities of active pharmaceutical ingredient to mount an imposing near-term threat,” meaning the branded purified fish oil product “will retain the lion’s share of icosapent ethyl sales well into 2022 and likely beyond,” an investment bank has forecasted.
Having obtained an invalidity ruling against six Vascepa patents in March this year from a federal district court, Dr....





